{"doi":"10.1128/aac.48.2.632-634.2004","title":"Differential Diffusions of Indinavir and Lopinavir in Genital Secretions of Human Immunodeficiency Virus-Infected Women","abstract":"<jats:title>ABSTRACT</jats:title>\n          <jats:p>\n            Plasma and cervicovaginal secretion (CVS) samples were collected from 19 human immunodeficiency virus type 1-infected women on lopinavir- or indinavir-containing regimens. Lopinavir and indinavir were detectable in 29 and 93% of CVS samples, respectively, a finding that may be ascribed to these drugs' differences in protein binding and pK\n            <jats:sub>a</jats:sub>\n            . The relationship between lopinavir and indinavir pharmacodynamics and viral evolution in the female genital tract should be assessed over time.\n          </jats:p>","journal":"Antimicrobial Agents and Chemotherapy","year":2004,"id":628161,"datarank":0.4335557636844247,"base_score":2.8903717578961645,"endowment":2.8903717578961645,"self_citation_contribution":0.4335557636844247,"citation_network_contribution":0.0,"self_endowment_contribution":0.4335557636844247,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":17,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1506532,"name":"Michel Tod","orcid":null,"position":1,"is_corresponding":false},{"id":1626251,"name":"Kamel Louchahi","orcid":null,"position":2,"is_corresponding":false},{"id":1626252,"name":"Linda Belarbi","orcid":null,"position":3,"is_corresponding":false},{"id":644562,"name":"Olivier Bouchaud","orcid":"0000-0002-5933-7228","position":4,"is_corresponding":false},{"id":1626253,"name":"Nathalie Mémain","orcid":null,"position":5,"is_corresponding":false},{"id":1626254,"name":"Olivier Petitjean","orcid":null,"position":6,"is_corresponding":false},{"id":1626255,"name":"Michel Robineau","orcid":null,"position":7,"is_corresponding":false},{"id":1626256,"name":"Loïc Guillevin","orcid":null,"position":8,"is_corresponding":false},{"id":410999,"name":"Olivier Lortholary","orcid":"0000-0002-8325-8060","position":9,"is_corresponding":false},{"id":345154,"name":"Odile Launay","orcid":"0000-0003-3242-7247","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Differential Diffusions of Indinavir and Lopinavir in Genital Secretions of Human Immunodeficiency Virus-Infected Women","abstract":"<jats:title>ABSTRACT</jats:title>\n          <jats:p>\n            Plasma and cervicovaginal secretion (CVS) samples were collected from 19 human immunodeficiency virus type 1-infected women on lopinavir- or indinavir-containing regimens. Lopinavir and indinavir were detectable in 29 and 93% of CVS samples, respectively, a finding that may be ascribed to these drugs' differences in protein binding and pK\n            <jats:sub>a</jats:sub>\n            . The relationship between lopinavir and indinavir pharmacodynamics and viral evolution in the female genital tract should be assessed over time.\n          </jats:p>","is_dataset_classified":null,"base_score":2.8903717578961645,"endowment":2.8903717578961645,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"14742224","pmcid":"PMC321543","openalex_id":"https://openalex.org/W2114976467","authors":[],"funders":[],"total_grants":0,"fwci":0.1018,"citation_percentile":0.37780041,"influential_citations":0,"citation_trend":[{"year":2012,"count":1},{"year":2013,"count":3},{"year":2014,"count":1},{"year":2015,"count":1},{"year":2017,"count":1},{"year":2022,"count":1}],"oa_status":"green","license":"https://journals.asm.org/non-commercial-tdm-license","oa_locations":[{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/321543","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/321543","host_type":"repository"},{"url":"https://journals.asm.org/doi/pdf/10.1128/AAC.48.2.632-634.2004","host_type":"publisher"},{"url":"https://doi.org/10.1128/aac.48.2.632-634.2004","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/14742224","host_type":"repository"},{"url":"http://europepmc.org/pmc/articles/PMC321543","host_type":"repository"}],"fields_of_study":["HIV Research and Treatment","HIV/AIDS drug development and treatment","HIV/AIDS Research and Interventions"],"mesh_terms":["Adult","Chromatography, High Pressure Liquid","Female","Genitalia, Female","Humans","Protein Binding","Pyrimidinones","Vagina","HIV-1","HIV Infections","Anti-HIV Agents","Indinavir","Lopinavir"],"keywords":["Indinavir","Lopinavir","Virology","Human immunodeficiency virus (HIV)","Biology","Medicine","Sida","Viral disease","Viral load","Antiretroviral therapy"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T11:27:39.805572Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}